ArticleMethods in enzymology2025
Enzyme-free biochemical production of seamlessly N-to-C cyclized peptides from natural or recombinant proteins.
Article in Methods in enzymology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synuclein.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
2 authors.
Funding
Abstract
Many naturally occurring or synthetic cyclic peptides are valuable as pharmaceuticals, but this stable and versatile class of molecules has not yet found applications beyond medicine. The main reason is the high cost of developing, producing, and altering these molecules via the gold-standard solid-phase synthesis methods. We focus on a class of cyclic peptides that have no disulfides, only canonical amino acids, and seamless peptide backbones. Known as orbitides or circular bacteriocins, such compounds are ribosomally synthesized and enzymatically cyclized by plants and bacteria. We report a simple method for producing them from naturally abundant proteins or from recombinantly expressed precursor polypeptides. The reaction proceeds under mild aqueous conditions, without the need for enzymes, and using only one chemical reagent, which is readily available. We demonstrate production of a 17-mer cyclic peptide from a wild-type human eye lens γ-crystallin and of a set of 10-residue cyclic peptides from recombinantly expressed polypeptide precursors. We investigate the effects of reaction conditions and sequence changes on reaction efficiency, identify the products by their complex mass spectrometry fragmentation patterns, and chromatographically separate linear and cyclic peptide forms. Our methodology opens the way to large-scale, cost-effective production of stable yet biodegradable, easily designable cyclic peptides for applications not only in medicine, but in areas like biotechnology, materials, agriculture, and pest control. It may also enable production of diverse cyclic peptide libraries from arbitrarily chosen natural protein sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.